Cathie Wood sells $14.3M in surging crypto stocks to buy Tesla
ARK Invest, the investment firm led by CEO Cathie Wood, last week unloaded crypto-focused shares worth $14.3 million to acquire $18.7 million in Tesla (Nasdaq: TSLA) stocks.
ARK Invest sold 16,627 Coinbase (Nasdaq: COIN) shares worth $6.47 million from its Innovation ETF (ARKK) on July 10. It sold 5,596 COIN shares worth $2.17 million from its Next Generation Internet ETF (ARKW) on July 11.
Coinbase is the largest crypto exchange in the U.S. which went public in April 2021.
COIN, which entered the S&P 500 club in May, reached an all-time high (ATH) of $395.5 on July 11 as Wood's firm kept unloading its shares.
The investment firm also unloaded 58,504 Robinhood (Nasdaq: HOOD) shares worth $5.7 million from ARKK on July 10.
Robinhood is a platform that offers stock and crypto trading, which went public in November 2021.
Though its recent launch of tokenized stocks received severe backlash from companies like OpenAI, the excitement around the new suite of products helped the stock reach a record high of $101.50 on July 11.Wood also praised Robinhood for launching tokenized stocks that allow 24/7 and fractionalized trading.
But the veteran fund manager was quick to dispose of both COIN and HOOD as they surged to new highs.
Instead, ARK Invest acquired Tesla shares worth $187.7 million on July 11 as the Elon Musk-led electric vehicle (EV) company announced it's coming to India soon.
The investment firm bought 45,761 TSLA shares worth $14.3 million for ARKK and 13,944 TSLA worth $4.3 million for ARKW on July 11.
Recently, Tesla was also at the center of the public feud between Musk and President Donald Trump that sent the stock tumbling.
The president had alleged that the tech tycoon was critical of the "big, beautiful bill" because the administration was going to terminate the EV mandate.As per BitcoinTreasuries, Tesla is the eighth-largest public corporate holder of Bitcoin.
Bitcoin hit the record high of $123,091.61 on July 14 and is trading at $121,900.46 at press time, as per Kraken's price feed. So, Tesla's BTC holdings of 11,509 coins are worth $1.4 billion at the time of writing.
Wood herself is a strong Bitcoin advocate who earlier predicted that the king coin could surpass $1.5 million in value.
Cathie Wood sells $14.3M in surging crypto stocks to buy Tesla first appeared on TheStreet on Jul 14, 2025
This story was originally reported by TheStreet on Jul 14, 2025, where it first appeared.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis
SOUTH SAN FRANCISCO, Calif., July 15, 2025--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that the Division of Hepatology and Nutrition of the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the completed PORTOLA Phase 2a clinical trial evaluating zetomipzomib, a first-in-class selective immunoproteasome inhibitor, in patients with autoimmune hepatitis (AIH). "We are pleased that the FDA has lifted the partial clinical hold on zetomipzomib in AIH after their review of our comprehensive safety assessment of the zetomipzomib program," said Chris Kirk, PhD, CEO and co-founder of Kezar. "We continue to believe that zetomipzomib has the potential to positively transform the lives of patients living with AIH. We look forward to engaging with the FDA to align on the design of the next clinical trial of zetomipzomib in AIH." Although Kezar has suspended development of zetomipzomib in lupus nephritis (LN) to focus on AIH, the company met with the Independent Data Monitoring Committee (IDMC) for the previously terminated PALIZADE clinical trial to review the safety profile of zetomipzomib. The IDMC has provided Kezar with recommendations for conducting future clinical trials in LN. Based on this feedback and internal analysis of safety data across all clinical studies involving zetomipzomib, Kezar plans to respond to the FDA Division of Rheumatology and Transplant Medicine with a request to lift the clinical hold on zetomipzomib in LN. About Zetomipzomib Zetomipzomib is a novel, first-in-class, selective immunoproteasome inhibitor with broad therapeutic potential across multiple autoimmune diseases. Preclinical research demonstrates that selective immunoproteasome inhibition results in a broad anti-inflammatory response in animal models of several autoimmune diseases, while avoiding immunosuppression. Data generated from completed clinical trials provide evidence that zetomipzomib exhibits a favorable safety and tolerability profile for development in severe, chronic autoimmune diseases. About Autoimmune Hepatitis Autoimmune hepatitis (AIH) is a rare chronic disease in which the immune system attacks the liver and causes inflammation and tissue damage, severely impacting patients' physical health and quality of life. Lifelong maintenance therapy is required to avoid relapse and burdensome adverse effects. If left untreated, AIH can lead to cirrhosis, liver failure and hepatocellular carcinoma. In the United States, AIH affects approximately 100,000 individuals, with incidence rates increasing. The cause of this condition remains unclear, with females affected four times as often as males. Currently, standard of care treatment for AIH is chronic, immunosuppressive treatment with corticosteroids that frequently cause life-altering side effects, including diabetes, osteoporotic fractures and cataracts. There is a significant need for treatment regimens that reduce or remove the need for chronic immunosuppression from use of corticosteroids. About Kezar Life Sciences Kezar Life Sciences is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases. Zetomipzomib, a selective immunoproteasome inhibitor, is currently being evaluated for autoimmune hepatitis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. For more information, visit and follow us on LinkedIn, Facebook, Twitter and Instagram. Cautionary Note on Forward-looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "can," "should," "expect," "believe," "potential," "anticipate" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Kezar's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause Kezar's clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the timing and outcome of regulatory submissions and interactions with the FDA, EMA or any other regulatory agencies with respect to zetomipzomib or Kezar's clinical trials, the initiation of an additional clinical trial of zetomipzomib in AIH, and expectations regarding the removal of the clinical hold of zetomipzomib in LN, and the likelihood of obtaining regulatory approval of zetomipzomib. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during clinical studies, difficulties enrolling and conducting our clinical trials, changes in expected or existing competition, changes in the regulatory environment, the uncertainties and timing of the regulatory approval process, and unexpected litigation or other disputes. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Kezar's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" contained therein. Except as required by law, Kezar assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available. View source version on Contacts Investor and Media Contact:Gitanjali JainSenior Vice President, Investor Relations and External AffairsKezar Life Sciences, Melden Sie sich an, um Ihr Portfolio aufzurufen.
Yahoo
30 minutes ago
- Yahoo
Nvidia's China Comeback Underway
Nvidia (NASDAQ:NVDA) just got word from Washington that its export licenses for H20 GPUs to China are on track. The team hopes to restart shipments soon, and investors are buzzing. That pause back in April cost roughly eight billion dollars in quarterly revenue and tipped the balance to competitors. Shares jumped five percent before the bell as traders cheered what Wedbush calls a watershed moment. Warning! GuruFocus has detected 4 Warning Signs with NVDA. This follows Jensen Huang's sit-down with President Trump at the White House, underscoring how closely Nvidia has worked with policymakers amid rising tech tensions. China accounts for about fifteen percent of Nvidia's sales. Restoring that channel could lift Wall Street estimates and fuel Nvidia's next growth wave as global AI demand keeps exploding. With both Beijing and Washington looking to ease friction, Nvidia's regained China foothold may power a broader tech rally and reaffirm Jensen Huang's lead in the AI arms race. This article first appeared on GuruFocus. Errore nel recupero dei dati Effettua l'accesso per consultare il tuo portafoglio Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati
Yahoo
32 minutes ago
- Yahoo
Here Is What You Need To Know Before Investing In Symbotic Inc. (SYM)
Symbotic Inc. (NASDAQ:SYM) is one of the 13 Best Booming Stocks to Buy Now, with year-to-date gains of nearly 91%. It builds technologies to enhance operational efficiencies in modern warehouses. A warehouse automation system in operation, with robotic arms managing inventory efficiently. On May 7, the company reported financial results for the second quarter of fiscal 2025. Symbotic Inc. (NASDAQ:SYM) posted a quarterly revenue of $550 million, up 40% year-over-year. Gross margins also expanded significantly during Q2, which drove a reduction in net loss to $21 million from $55 million in the prior year. Moreover, Symbotic Inc. (NASDAQ:SYM) delivered a record number of system starts and completes during the quarter. The company is committed to delivering improved execution ahead while investing in future growth and innovation. For Q3, management anticipates revenue in the range of $520 million to $550 million and adjusted EBITDA between $26 million and $30 million. Wall Street analysts maintain a positive outlook for the stock, with a consensus Buy rating. However, the average consensus does not see the rally extending in the months to come, with a one-year average price target of $33.4, representing a downside potential of 29%. In other news, last month, Symbotic Inc. (NASDAQ:SYM) appointed Izzy Martins as the company's new CFO, effective August 9, 2025. He will replace Carol Hibbard, who is departing to explore other opportunities, but will remain with the firm until the end of the calendar year to ensure a smooth transition. While we acknowledge the potential of SYM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best German Stocks to Invest in Now and Goldman Sachs Stock Portfolio: 10 Large-Cap Stocks To Buy. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
